+91 6376341881
SoMex Research & Health Organization
Clinical Research Organization

Latest News



Ribociclib has been granted breakthrough therapy designation for use in combination with tamoxifen or an AI)= as frontline treatment for pre- or perimenopausal women with HR+ HER2– advanced or metasta


Ribociclib has been granted breakthrough therapy designation for use in combination with tamoxifen or an AI)= as frontline treatment for pre- or perimenopausal women with HR+ HER2– advanced or metastatic breast cancer.




Other Latest News


SoMex Research & Health Organization

Get in Touch

+91-141-2504996
somexresearch@gmail.com
www.somexresearch.com

About

Services